“
“Anaplasmosis in animals is caused by Anaplasma spp. including A. phagocytophilum, NSC23766 nmr A. marginale, A. centrale, A. ovis, and A. bovis, which are obligate intracellular rickettsial pathogens transmitted by ticks. Infection in animals is considered an important constraint on livestock production. In Korea, the prevalence of Anaplasma spp. has been investigated in several species, including cattle, dogs, and rodents,

but there are no available data on anaplasmosis in goats. The purpose of this study was to investigate the presence of Anaplasma spp. in native Korean goats (Capra hircus coreanae) using a commercial competitive ELISA which specifically detects antibodies against A. marginale, A. centrale, and A. ovis. A total of 36 (6.6%) of 544 goat serum samples tested seropositive for Anaplasma spp. With regard to age, 4.9% (7/144), 9.5% (27/283), and 1.7% (2/117) of samples tested seropositive in the young ( smaller than 1 year), adult ( bigger than = 1 year), and unknown age groups, respectively, with significant differences among groups (P smaller than 0.05). The seroprevalence by region was 1.7% (2/121), 2.6% (2/77), and 9.2% (32/346) in the northern, central, and southern regions, respectively, with significant differences among regions (P smaller than 0.05). With regard to the season of sample collection, 3.3% (4/122) and 7.6% (32/422) Cell Cycle inhibitor samples tested seropositive

during the cold and warm seasons, respectively. To the best of our knowledge, this is the first known study reporting the seroprevalence of Anaplasma spp. in native Korean goats. Despite the relatively low prevalence of Anaplasma spp. in native Korean goats compared with that in animals from other countries, these results should not be disregarded because infection with Anaplasma spp. in animals has long been recognised, and the potential for horizontal transmission cannot be excluded.”
“Rituximab (RTX), a chimeric anti-CD20 antibody, is associated with direct induction of apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC) with clinical efficacy in mantle cell

lymphoma (MCL). Lenalidomide (LEN), a novel immunomodulatory agent, sensitizes tumor cells and LY411575 clinical trial enhances ADCC. Our study attempted to elucidate the mechanism of LEN-enhanced RTX-mediated cytotoxicity of MCL cells. We found that LEN and RTX induced growth inhibition of both cultured and fresh primary MCL cells. LEN enhanced RTX-induced apoptosis via upregulating phosphorylation of c-Jun N-terminal protein kinases (JNK), Bcl-2, Bad; increasing release of cytochrome-c; enhancing activation of caspase-3, -8, -9 and cleavage of PARP. Meanwhile, LEN activated NK cells and increased CD16 expression on CD56(low)CD16(+) NK cells. Whole PBMCs but not NK cell-depleted PBMCs treated with LEN augmented 30% of RTX-dependent cytotoxicity.